Department of Otorhinolaryngology, Head and Neck Surgery, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC; Department of Head and Neck Oncology Group, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC.
Department of Head and Neck Oncology Group, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC; Department of Pathology, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, ROC.
Oral Oncol. 2018 Nov;86:188-194. doi: 10.1016/j.oraloncology.2018.09.021. Epub 2018 Sep 28.
According to the AJCC 2017 Staging Manual, oral cavity squamous cell carcinoma (OCSCC) with pN2 disease (based on the AJCC 2010 criteria) and extra-nodal extension (ENE) should be classified as pN3b. We performed a detailed outcome analyses in this patient subgroup.
We retrospectively reviewed the clinical records of consecutive OCSCC patients who underwent radical surgery between 1996 and 2017. Patients with pN3b disease (n = 365) were divided into a pN+ ≥8/ENE ≥5 subgroup (defined by the presence of pN+ ≥8 nodes or ENE ≥5 nodes, n = 77) and a pN+ ≤7/ENE ≤4 subgroup (defined by the presence of pN+ ≤7 nodes and ENE ≤4 nodes, n = 288). Patients with pN0/pN1/pN2 (n = 1192/179/197) disease were included for comparison purposes.
Patients in the pN+ ≥8/ENE ≥5 subgroup had less favorable 5-year outcomes than those in the pN+ ≤7/ENE ≤4/pN2/pN1/pN0 groups (local control, 64%/79%/86%/83%/88%, p < 0.001; neck control, 55%/75%/80%/86%/93%, p < 0.001; distant metastases, 67%/28%/20%/12%/3%, p < 0.001; disease-free survival, 21%/51%/64%/72%/82%, p < 0.001; disease-specific survival, 25%/55%/71%/82%/92%, p < 0.001; overall survival, 19%/40%/54%/64%/82%, p < 0.001; respectively). Among patients with pN3b disease, multivariable analysis identified the pN+ ≥8/ENE ≥5 subgroup, lower neck (level IV/V) metastases, and depth of invasion ≥25 mm as independent adverse prognostic factors for 5-year distant metastases and survival rates.
Patients in the pN+ ≥8/ENE ≥5 subgroup have an unfavorable prognosis and their classification as pN3b is advisable. In contrast, patients in the pN+ ≤7/ENE ≤4 subgroup should be classified as pN3a.
根据 AJCC 2017 分期手册,口腔鳞状细胞癌(OCSCC)伴 pN2 疾病(基于 AJCC 2010 标准)和淋巴结外扩展(ENE)应归类为 pN3b。我们对此患者亚组进行了详细的预后分析。
我们回顾性分析了 1996 年至 2017 年间接受根治性手术的连续 OCSCC 患者的临床记录。pN3b 疾病患者(n=365)分为 pN+≥8/ENE≥5 亚组(定义为存在 pN+≥8 个淋巴结或 ENE≥5 个淋巴结,n=77)和 pN+≤7/ENE≤4 亚组(定义为存在 pN+≤7 个淋巴结和 ENE≤4 个淋巴结,n=288)。纳入 pN0/pN1/pN2(n=1192/179/197)疾病患者进行比较。
pN+≥8/ENE≥5 亚组患者的 5 年预后不如 pN+≤7/ENE≤4/pN2/pN1/pN0 组(局部控制率分别为 64%/79%/86%/83%/88%,p<0.001;颈部控制率分别为 55%/75%/80%/86%/93%,p<0.001;远处转移率分别为 67%/28%/20%/12%/3%,p<0.001;无病生存率分别为 21%/51%/64%/72%/82%,p<0.001;疾病特异性生存率分别为 25%/55%/71%/82%/92%,p<0.001;总生存率分别为 19%/40%/54%/64%/82%,p<0.001)。在 pN3b 疾病患者中,多变量分析确定 pN+≥8/ENE≥5 亚组、较低的颈部(IV/V 级)转移和浸润深度≥25mm 是 5 年远处转移和生存率的独立不良预后因素。
pN+≥8/ENE≥5 亚组患者预后不良,建议将其归类为 pN3b。相比之下,pN+≤7/ENE≤4 亚组患者应归类为 pN3a。